Ex-Pfizer leader Geno Germano becomes Entera Bio (ENTX) board chairman
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Entera Bio Ltd. has appointed pharmaceutical industry veteran Geno J. Germano as Chairman of the Board and a Class III director, effective February 4, 2026. He will serve until the 2026 annual shareholder meeting or until a successor is chosen.
Germano brings more than three decades of leadership experience, including senior roles at Pfizer where he led a roughly $14 billion innovative medicines portfolio, and board positions at multiple biotech companies. He will receive standard non-employee director cash and equity compensation under Entera’s 2018 Equity Incentive Plan.
Gerald Lieberman resigned as Chairman and as a director effective February 4, 2026, with the company stating his resignation did not result from any disagreement over operations, policies, or practices. Entera highlighted this leadership change as it plans 2026 clinical milestones, including a Phase 3 study of EB613 for osteoporosis and a first-in-human study of Long-Acting Oral PTH for hypoparathyroidism.
Positive
- None.
Negative
- None.
Insights
Entera adds a high-profile pharma leader as chairman while planning key 2026 trials.
The company has named Geno J. Germano, a former senior Pfizer executive, as Chairman and Class III director. His background includes leading Pfizer’s Global Innovative Pharmaceutical Business, overseeing an approximately
This governance change coincides with Entera’s plans to advance two oral PTH peptide programs into clinical testing in
The combination of late-stage development ambitions and an experienced chairman may influence how Entera navigates clinical design, regulatory interactions and potential partnerships. Future disclosures on trial initiation and progress in
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2026
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
(State or other jurisdiction
of incorporation) |
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification) |
(Address of principal executive offices) (Zip Code)
(Registrant’s Telephone Number, Including Area Code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers
Appointment of Geno J. Germano as a Director and Chairman of the Board
The Board of Directors (the “Board”) of Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”) appointed Geno J. Germano as a Class III director of the Company and
as Chairman of the Board, effective February 4, 2026. Mr. Germano will serve as a director until the Company’s 2026 Annual Meeting of Shareholders and until his successor shall have been elected and qualified, or until his earlier death,
resignation, retirement, disqualification or removal.
Mr. Germano, age 65, is a 35-year veteran of the pharmaceutical and life sciences industry with extensive experience in development
and commercialization of a broad range of medicines across most therapeutic categories. Most recently, from August 2018 to June 2024, Mr. Germano served as President and Chief Executive Officer and a board member of Elucida Oncology, Inc., a
biotechnology company. He previously served as President of Intrexon Corporation, or Intrexon, a leader in engineering and industrialization of biology, from June 2016 to March 2017. Prior to joining Intrexon, from 2014 to February 2016, Mr.
Germano was Group President of the Global Innovative Pharma Business of Pfizer, where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic
areas. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee at Pfizer from 2013 to February 2016. Previously, from 2009 through 2013, Mr. Germano served as President and General Manager of Pfizer’s Specialty Care and
Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across global markets. Additionally, Mr. Germano has served on the board of directors of Precision Biosciences, Inc., a clinical
stage biotechnology company, since March 2020. In the past five years, Mr. Germano served on the boards of directors of Sage Therapeutics (from 2016 until the company was acquired in 2025), Orbital Therapeutics, a private pre-clinical stage
biotechnology company (from March 2025 until the company was acquired in December 2025), Bioverativ Inc. (acquired by Sanofi S.A. in March 2018) and The Medicines Company (acquired by Novartis AG in January 2020). Mr. Germano received his B.S. in
Pharmacy from Albany College of Pharmacy.
There are no arrangements or understandings between Mr. Germano and any other person pursuant to which Mr. Germano was appointed as a
director of the Company. The Board has determined that Mr. Germano is independent under the applicable rules of the Securities and Exchange Commission and the Nasdaq Stock Market.
Since the beginning of Company’s last fiscal year, the Company has not engaged in any transaction, or any currently proposed
transaction, in which Mr. Germano had or will have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K.
Mr. Germano will participate in the Company’s standard non-employee director compensation arrangements, which were approved by the
Company’s shareholders in July 2025, including the right to annual cash payments with respect to Board and applicable committee service and an annual equity grants under the Company’s 2018 Equity Incentive Plan.
Director Resignation
On February 4, 2026, Gerald Lieberman notified the Board of his resignation as Chairman of the Board and as a Director, effective
immediately. Mr. Lieberman’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
Item 7.01 Regulation FD Disclosure.
On February 9, 2026, the Company issued a press release announcing the appointment of Mr. Germano as Chairman of the Board. A copy of
the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.
The information disclosed under this Item 7.01, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such
information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
Number
|
Description
|
|
99.1
|
Press release, dated
February 9, 2026
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
|
|
|
ENTERA BIO LTD.
|
|
|
|
|
|
Date: February 9, 2026
|
By:
|
/s/ Miranda Toledano
|
|
|
|
Name: Miranda Toledano
Title: Chief Executive Officer
|
Exhibit 99.1
 |
|
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer,
Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026
TEL AVIV, February 9, 2026 -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral
peptide and protein replacement therapies, today announced that its Board of Directors has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026. Mr. Germano succeeds Gerald Lieberman, who is stepping down as
Chairman.
The appointment follows a period of accelerating progress across Entera’s pipeline as the Company plans to advance two oral PTH peptide
programs into clinical testing within 2026, a Phase 3 registrational study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism.
“Entera’s lead clinical asset, EB613, has the potential to fundamentally change how osteoporosis is treated,” said Mr. Germano. “While
anabolic therapies are well established as highly effective, their use has largely been limited by the burden of injections. An oral anabolic therapy could move bone-building treatment earlier in the treatment paradigm and into frontline use for a
much broader patient population. Combined with Entera’s plans for hypoparathyroidism and metabolic diseases, I look forward to working with the team as the Company enters this pivotal phase of development and execution.”
“I would like to thank Jerry immensely for his contributions during his tenure on the board,” said Miranda Toledano, Chief Executive
Officer of Entera. “We are truly honored to welcome Geno as Chairman. The last three years have set the foundation for Entera’s highly differentiated oral peptide pipeline, N-Tab® platform, regulatory alignment and transition to late-stage clinical
testing. Geno’s decades of global biopharmaceutical leadership experience and proven ability to scale highly differentiated therapeutic platforms through late-stage development and toward commercialization will be a critical asset to Entera. We are
looking forward to working together with Geno’s as we advance Entera to its next phase,” said Toledano.
Mr. Germano is a pharmaceutical and life sciences executive with more than three decades of leadership experience spanning development,
commercialization, and global operations. He held senior leadership roles at Pfizer, including as Group President of Pfizer’s Global Innovative Pharmaceutical Business, where he led the company’s approximately $14 billion innovative medicines
portfolio with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee at Pfizer from 2013 to February
2016. Previously, from 2009 through 2013, Mr. Germano served as President and General Manager of Pfizer’s Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across
global markets. Additionally, Mr. Germano has served on the board of directors of Precision Biosciences, Inc., a clinical stage biotechnology company, since March 2020. In the past five years, Mr. Germano served on the boards of directors of Sage
Therapeutics (from 2016 until the company was acquired in 2025), Orbital Therapeutics, a private pre-clinical stage biotechnology company (from March 2025 until the company was acquired in December 2025), Bioverativ Inc. (acquired by Sanofi S.A. in
March 2018) and The Medicines Company (acquired by Novartis AG in January 2020). Mr. Germano received his B.S. in Pharmacy from Albany College of Pharmacy.
About Entera Bio
Entera is a clinical stage company focused on developing
oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab®)
and its pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building)
once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The
EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment
of obesity and metabolic syndromes; and first oral GLP-2 peptide as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on
Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.
Cautionary Statement Regarding Forward Looking Statements
Various statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform
Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking
statements. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or
the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ
materially from those reflected in Entera's forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA's interpretation and review of our results from and analysis of our
clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the
potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be
contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera's product candidates; Entera's reliance on third parties to
conduct its clinical trials; Entera's ability to establish and maintain development and commercialization collaborations; Entera's operation as a development stage company with limited operating history; Entera's competitive position with respect to
other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera's ability to continue as a going concern absent
access to sources of liquidity; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the
requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Cautionary Statement Regarding Forward-Looking
Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's most recent Annual Report on Form 10-K filed with the SEC, as well as Entera's subsequently filed Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or
effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in
this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information,
future events or otherwise, except to the extent required by law.
Company Contact:
Entera Bio:
Ms. Miranda Toledano
Chief Executive Officer, Entera Bio
Email: miranda@enterabio.com
Entera Bio:
Ms. Miranda Toledano
Chief Executive Officer, Entera Bio
Email: miranda@enterabio.com
FAQ
What board changes did Entera Bio (ENTX) announce in this 8-K?
Entera Bio appointed Geno J. Germano as Chairman of the Board and a Class III director, effective February 4, 2026. He replaces Gerald Lieberman, who resigned as chairman and director, with the company stating his resignation was not due to any disagreement over operations or policies.
Who is Geno J. Germano, the new Chairman of Entera Bio (ENTX)?
Geno J. Germano is a 35-year pharmaceutical and life sciences veteran. He previously served as Group President of Pfizer’s Global Innovative Pharmaceutical Business, leading an approximately $14 billion portfolio, and has held senior roles and board seats at multiple biotechnology companies across oncology and specialty care.
How long will Geno J. Germano serve as an Entera Bio (ENTX) director?
Geno J. Germano will serve as a Class III director until Entera Bio’s 2026 Annual Meeting of Shareholders and until his successor is elected and qualified. His term could end earlier in the event of death, resignation, retirement, disqualification, or removal under standard governance provisions.
Did Entera Bio (ENTX) disclose any disagreements related to Gerald Lieberman’s resignation?
Entera Bio stated that Gerald Lieberman’s resignation as Chairman and director on February 4, 2026 was not the result of any disagreement with the company. This includes no disagreement regarding its operations, policies, or practices, indicating an orderly transition rather than a conflict-driven departure.
What 2026 clinical milestones did Entera Bio (ENTX) highlight with this leadership change?
Entera Bio linked the appointment to plans for two key 2026 studies: a Phase 3 registrational trial of EB613, an oral PTH(1-34) for osteoporosis, and a first-in-human study of Long-Acting Oral PTH for hypoparathyroidism, both part of its broader oral peptide pipeline strategy.
How will Geno J. Germano be compensated as an Entera Bio (ENTX) director?
Geno J. Germano will participate in Entera Bio’s standard non-employee director compensation program approved in July 2025. This includes annual cash payments tied to Board and committee service and annual equity grants issued under the company’s 2018 Equity Incentive Plan, aligning him with shareholder interests.
Filing Exhibits & Attachments
5 documents
Entera Bio Ltd
NASDAQ:ENTX
ENTX Rankings
ENTX Latest News
ENTX Latest SEC Filings
Feb 4, 2026
[8-K] Entera Bio Ltd. Reports Material Event
ENTX Stock Data
47.69M
34.60M
24.31%
22.36%
0.08%
Biotechnology
Biological Products, (no Disgnostic Substances)
Israel
JERUSALEM